Vicier Cecile - Institut National de la Santé et de la Recherche Médicale (INSERM) U981, Gustave Roussy Institute (IGR),

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 95 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

340O Efficacy, Safety and Biomarker Analysis of ICARUS-BREAST01: A Phase II Study of Patritumab Deruxtecan (Her3-Dxd) in Patients (pts) with HR+/HER2- Advanced Breast Cancer (ABC)

B. Pistilli, L. Pierotti, M. Lacroix-Triki,C. Vicier, J-S. Frenel,V. D'Hondt, F. Dalenc, T. Bachelot,A. Ducoulombier,M-A. Benderra,D. Loirat,D. Mayeur, G.B. Nachabeh, A. Sporchia,F. Suto, S. Michiels, N. Corcos,M.F. Mosele, F. André, G. Montagnac

Annals of Oncology (2024)

Cited0Views0Bibtex

Abstract PO3-04-13: SUMIT-ELA: Phase 1b/2 Combination of Cyclin-Dependent Kinase 7 Inhibitor (cdk7i) Samuraciclib and Selective Estrogen Receptor Degrader (SERD) Elacestrant in Advanced Hormone Receptor Positive (HR+) Breast Cancer after CDK4/6i

Amita Patnaik,Silvia Antolín,Meritxell Bellet Ezquerra,François‐Clément Bidard,Valentina Boni, Maxime Brunet, Mario Campone, Carlos A. Garay,Raquel Gómez Bravo,Sacha J. Howell,Rinath Jeselsohn,Simon Lord, Paolo Mazzei,Maria J. de Miguel,Erin Roesch,Agostina Stradella,Hélène Vanacker,Cécile Vicier,Seth A. Wander, Glen Clack,Stuart McIntosh

Cancer Researchno. 9_Supplement (2024): PO3-13

Cited0Views0Bibtex

692 ICT01 and Pembrolizumab in Combination Elicit Deep and Durable Responses in Heavily Pretreated Patients with Refractory Melanoma: Interim Results from Study EVICTION

Stephane Champiat,Christophe Massard,Johann De Bono,Cecile Vicier, Emiliano Calvo, Evan Hall,Antoine Italiano, Benoit You,Hatem Soliman,Tatiana Hernandez,Christiane Jungels,Julien Vibert,Vladimir Galvao,Esma Saada,Aude De Gassart,Emmanuel Valentin,Maelle Mairesse,Patrick Brune,Katrien Lemmens,Daniel Olive, Stephan Braun,Martin Wermke

Regular and Young Investigator Award Abstracts (2024)

Cited0Views0Bibtex

1003P A First-in-human (FIH) Phase I Study of IPH5301, an Anti-Cd73 Monoclonal Antibody (mab), in Patients with Advanced Solid Tumors (AST) (CHANCES, NCT05143970)

M. Beaufils,A. Mailliez,P. Sfumato,C. Vicier,M. Provansal Gross, M. Guerin,B. Chanez,N. Kotecki, A. Widemann, S. Panzolato,A. Boyer Chammard, P. André,C.L. Paturel, C. Gouarne,A.H. Awada,J.M. Boher, A. Gonçalves

Annals of Oncology (2024)

Cited0Views0Bibtex

Abstract PO1-20-06: Phase 2 Study of Novel HER2-targeting, TLR7/8 Immune-Stimulating Antibody Conjugate (ISAC) BDC-1001 +/- Pertuzumab in Patients with HER2-positive Metastatic Breast Cancer (MBC) Previously Treated with Trastuzumab Deruxtecan

Mark Pegram,Carmen Calfa,Chris Chen,Alfonso Cortes Salgado,Arielle Heeke,Irene Kang,Barbara Pistilli,Paula Pohlmann,Hope Rugo,Cristina Saura,Cecile Vicier,Cecelia I. Pearson,Coya Tapia, Ming Yin, Tai Yu,Michael N. Alonso,Edith A. Perez,Joshua Drago

Cancer Researchno. 9_Supplement (2024): PO1-20

Cited0Views0Bibtex

Phase 2 Study of Novel HER2-targeting, TLR7/8 Immune-Stimulating Antibody Conjugate (ISAC) BDC-1001 (trastuzumab Imbotolimod) Plus /- Pertuzumab (P) in Patients (pts) with HER2-positive Metastatic Breast Cancer (MBC) Previously Treated with Trastuzumab Deruxtecan (T-Dxd)

Mark D. Pegram,Carmen Calfa,Christopher Chen, Alfonso Cort Prime Es Salgado,Arielle Lutterman Heeke,Irene Kang,Barbara Pistilli,Paula R. Pohlmann,Hope S. Rugo,Cristina Saura,Cecile Vicier,Cecelia Pearson,Milan Mangeshkar, Tai Yu,Michael N. Alonso, Dawn E. Colburn,Edith A. Perez,Joshua Z. Drago

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

Cited0Views0Bibtex

SUMIT-ELA: Phase 1b/2 Combination of Cyclin-Dependent Kinase 7 Inhibitor (cdk7i) Samuraciclib and Selective Estrogen Receptor Degrader (SERD) Elacestrant in Advanced Hormone Receptor Positive (HR Plus ) Breast Cancer after CDK4/6i

Amita Patnaik,Silvia Antolin Novoa,Meritxell Bellet-Ezquerra,Francois-Clement Bidard, Valentina Boni,Maxime Brunet, Mario Campone, Carlos Garay,Raquel Gomez-Bravo,Sacha Howell, Rinath Jeselsohn,Simon Lord,Paolo Mazzei,Maria De Miguel,Erin Roesch,Agostina Stradella,Helene Vanacker,Cecile Vicier,Seth Wander,Glen Clack, Stuart McIntosh

CANCER RESEARCHno. 9 (2024)

Cited0Views0Bibtex

EVICTION Study: ICT01, an Anti-Butyrophilin 3A Monoclonal Antibody Activating Γ9δ2 T Cells in Combination with Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

Stephane Champiat,Martin Wermke,Cecile Vicier, Johann S. De Bono,Emiliano Calvo,Jorge Ramon, Evan Thomas Hall,Elena Garralda,Vladimir Galvao,Emanuela Romano,Antoine Italiano,Esma Saada, Benoit You,Aude De Gassart,Maelle Mairesse,Emmanuel Valentin,Patrick Brune,Daniel Olive,Katrien Lemmens,Paul Frohna

Journal of Clinical Oncologyno. 16_suppl (2024): 9534-9534

Cited0Views0Bibtex

A Phase 1/1b, First-in-human, Multi-Part Study of DF6215, an Engineered IL-2Rα-active Agonist, to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological and Clinical Activity in Patients with Advanced Solid Tumors

Benedito A. Carneiro, Meredith McKean,Cecile Vicier,Jennifer Brooke Valerin, Ahmad A. Tarhini, Vinod Ganju,Mary M. Ruisi, Patrick Kirby,Jean-Marie Cuillerot,Emanuela Romano

Journal of Clinical Oncologyno. 16_suppl (2024): TPS2704-TPS2704

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn